-
摘要: 高血压和糖尿病是引起心脑血管事件的主要危险因素,对于血压处于130~139/80~89 mmHg(1 mmHg=0.133 kPa)的糖尿病患者,根据指南血压应控制在130/80 mmHg以下,但直接处方降压药物尚缺乏指南支持。三类新型降糖药中,SGLT-2抑制剂降压作用较明显,平均24 h动态收缩压/舒张压降低为3.8/1.8 mmHg; GLP-1受体激动剂仅降低收缩压,24 h动态收缩压下降范围在1.1~2.8 mmHg; DPP-4抑制剂降压作用研究结果不一致。三类新型降糖药对血压的影响,临床医生在治疗糖尿病患者时应酌情考虑。Abstract: Hypertension and diabetes are the major risk factors for cardiovascular and cerebrovascular events. For diabetes patients with blood pressure level 130-139/80-89 mmHg(1 mmHg=0.133 kPa), the target blood pressure should be controlled below 130/80 mmHg, but direct prescribing antihypertensive drugs is still lack of guidance. Among the three new hypoglycemic drugs, SGLT-2 inhibitor has obvious antihypertensive effect, and the average 24-hour dynamic SBP/DBP decrease to 3.8/1.8 mmHg; GLP-1 receptor agonist only decrease SBP, and the decrease range of 24-hour dynamic SBP is 1.1-2.8 mmHg; The results of studies on the antihypertensive effect of DPP-4 inhibitors are inconsistent. Three new types of hypoglycemic agents affect blood pressure. Clinicians should take into consideration for the treatment of diabetic patients.
-
Key words:
- hypertension /
- diabetes /
- SGLT-2 inhibitor /
- GLP-1 receptor agonist /
- DPP-4 inhibitor /
- blood pressure
-
-
[1] Cosentino F,Grant PJ,Aboyans V,et al.2019 ESC Guidelines on diabetes,pre-diabetes,and cardiovascular diseases developed in collaboration with the EASD[J].Eur Heart J,2020 Jan 7,41(2):255-323.
[2] 中国高血压防治指南修订委员会.中国高血压防治指南(2018修订版)[J].中国心血管杂志,2019,24(1):24-56.
[3] Whelton PK,Carey RM,Aronow WS,et al.2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention,Detection,Evaluation,and Management of High Blood Pressure in Adults:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J].Hypertension,2018 Jun,71(6):e13-e115.
[4] Liakos CI,Papadopoulos DP,Sanidas EA,et al.Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents(SGLT-2 Inhibitors,GLP-1 Receptor Agonists,and DPP-4 Inhibitors)[J].Am J Cardiovasc Drugs,2021 Mar,21(2):123-137.
[5] Kario K,Okada K,Kato M,et al.24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension:results from the randomized,Placebo-Controlled SACRA Study[J].Circulation,2019,139(18):2089-2097.
[6] Weber MA,Mansfield TA,Alessi F,et al.Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade[J].Blood Press,2016,25:93-103.
[7] Townsend RR,Machin I,Ren J,et al.Reductions in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension[J].J Clin Hypertens(Greenwich),2016,18(1):43-52.
[8] Baker WL,Buckley LF,Kelly MS,et al.Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure:a systematic review and metaanalysis[J].J Am Heart Assoc,2017,6:e005686.
[9] Mazidi M,Rezaie P,Gao HK,Kengne AP.Effect of sodiumglucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus:a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients[J].J Am Heart Assoc,2017,6:e00407.
[10] Thomas Nystrom,Mark K Gutniak,Qimin Zhang,et al.Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease[J].Am J Physiol Endocrinol Metab,2004 Dec,287(6):E1209-15.
[11] Holman RR,Bethel MA,Mentz RJ,et al.Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes[J].N Engl J Med,2017,377(13):1228-399.
[12] Marso SP,Daniels GH,Brown-Frandsen K,et al.Liraglutide and cardiovascular outcomes intype 2 diabetes[J].N Engl J Med,2016,375(4):311-22.
[13] Maringwa J,Sardu ML,Hang Y,et al.Characterizing Effects of Antidiabetic Drugs on Heart Rate,Systolic and Diastolic Blood Pressure[J].Clin Pharmacol Ther,2021 Jun,109(6):1583-1592.
-
计量
- 文章访问数: 376
- PDF下载数: 302
- 施引文献: 0
下载: